3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 1/2
2
Phase 1
2
Phase 3
1
Status
Completed
7
Terminated
2
Withdrawn
1
Recruiting
1
Not yet recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Other solid neoplasm
1
Genitourinary
1
Conditions
Prostatic Neoplasms
1
Advanced Solid Tumor
1
Interventions
Cyclophosphamide
98
pembrolizumab
85
Gemcitabine
81
Carboplatin
62
fludarabine
61
Nivolumab
57
Cisplatin
54
Paclitaxel
51
Radiotherapy
50
Docetaxel
49
Rituximab
46
Dexamethasone
42
Lenalidomide
41
Ipilimumab
38
Azacitidine
35
Etoposide
34
Cytarabine
33
Temozolomide
32
Bevacizumab
32
Radiation
29
venetoclax
28
Bortezomib
27
Magnetic Resonance Spectroscopy
26
Irinotecan
26
Pemetrexed
25
atezolizumab
24
Oxaliplatin
24
Capecitabine
24
fludarabine phosphate
22
Filgrastim
22
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 1
×
Terminated
×
BID protein, human
×
Clear all
NCT06560632
2026-01-16
POLAR
Repare Therapeutics
Phase 1
Terminated
26 enrolled
14 charts
NCT04421222
2025-02-28
EPI-7386
ESSA Pharmaceuticals
Phase 1
Terminated
71 enrolled